In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...

Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...

Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat adults with newly diagnosed ...